GlassScriptPhysician profile
Akif A Mohammed
NPI 1437397478
$8,267.46
in general payments reported to CMS, 2019-2025
43 companies · $1,489 in 2025
The $1,489 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,248 · 2020: $691 · 2021: $1,344 · 2022: $1,475 · 2023: $583 · 2024: $1,438 · 2025: $1,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,462 · Travel and Lodging: $954 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,461.61 |
| Travel and Lodging | $953.63 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,184.25 | 2019-2025 | Mitraclip, Triclip, Xience Skypoint |
| Novartis Pharmaceuticals Corporation | $1,087.30 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $679.55 | 2021 | |
| Boston Scientific Corporation | $468.86 | 2019-2025 | Apollo Esg System |
| E.R. Squibb & Sons, L.L.C. | $440.77 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $418.54 | 2019-2025 | |
| Amgen INC. | $357.06 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $247.01 | 2019-2025 | Farxiga, Andexxa |
| Amarin Pharma, INC. | $239.43 | 2020-2023 | |
| Edwards Lifesciences Corporation | $222.87 | 2024-2025 | Pascal, Sapien 3 Ultra Resilia |
| Actelion Pharmaceuticals US, INC. | $183.10 | 2019-2025 | Opsumit, Uptravi |
| Medtronic Vascular, INC. | $172.38 | 2019 | |
| Heartflow, INC. | $165.51 | 2022 | |
| Penumbra, INC. | $149.11 | 2020 | |
| Cardiovascular Systems INC. | $117.68 | 2019-2020 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $117.28 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $88.37 | 2019-2025 | Amvuttra, Givlaari, Onpattro |
| Inspire Medical Systems, INC. | $83.48 | 2025 | Inspire |
| Cleerly, INC. | $80.08 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Janssen Pharmaceuticals, INC | $71.85 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.46 | 2019-2024 | Jardiance |
| Inari Medical, INC. | $59.45 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Ge Healthcare | $55.50 | 2025 | |
| Philips North America LLC | $53.34 | 2024 | (Br5) Peripheral Ivus |
| Regeneron Healthcare Solutions, INC. | $46.90 | 2019 | |
| Endologix LLC | $46.47 | 2025 | Endocross Device, Torus Stent Graft System |
| Merck Sharp & Dohme LLC | $40.37 | 2021-2024 | Verquvo |
| Medtronic, INC. | $31.62 | 2025 | Symplicity G3, Selectsite |
| Ebr Systems, INC. | $31.23 | 2025 | |
| Novo Nordisk INC | $30.09 | 2021-2025 | Wegovy |
| Astellas Pharma US INC | $30.06 | 2019-2020 | |
| Esperion Therapeutics, INC. | $26.98 | 2021 | |
| Avinger INC. | $20.09 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $19.45 | 2021 | |
| Vital Connect, INC | $18.98 | 2025 | Vitalpatch Rtm |
| W. L. Gore & Associates, INC. | $17.98 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $17.61 | 2024 | Arcalyst |
| Abiomed | $14.96 | 2019 | |
| Tactile Systems Technology INC | $14.01 | 2019 | |
| Shockwave Medical, INC | $13.81 | 2025 | |
| Siemens Medical Solutions USA, INC. | $12.59 | 2021 | |
| United Therapeutics Corporation | $12.03 | 2019 | |
| Bardy Diagnostics, INC. | $10.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akif Mohammed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.